Table 1.
Treatments used for RNA-Seq analysis of PTI suppression by physical domains of AvrPto
| Treatment | Concentration | Comment | Average total reads (in millions) | Average reads mapped (in percent) |
|---|---|---|---|---|
| Mock | 10 mM MgCl2, 0.02 % silwet | No bacteria | 15.2 | 93.1 |
| D29E pCPP45::avrPto | OD600 0.02 | Wild-type | 15.6 | 93.6 |
| D29E pCPP45::avrPto(I96A) | OD600 0.02 | Core domain (CD) inactivated | 16.3 | 94.1 |
| D29E pCPP45::avrPto(2xA)a | OD600 0.02 | C-terminal domain (CTD) inactivated | 16.6 | 94.3 |
| D29E pCPP45::avrPto(I96A, 2xA)a | OD600 0.02 | ‘CD−/CTD−‘ | 14.9 | 93.8 |
a2xA represents the presence of both S147A and S149A